Loading...
•
Sep 30, 2021
Edwards Lifesciences Q3 2021 Earnings Report
Reported a 15 percent increase in sales, driven by growth in all product groups, despite the impact of the Delta variant.
Key Takeaways
Edwards Lifesciences reported a 15% increase in sales to $1.3 billion for the third quarter of 2021. The company's TAVR sales grew by 15%, and it made progress on five pivotal trials in TMTT. The company maintained its full-year 2021 sales guidance range and EPS guidance.
Sales grew 15 percent to $1.3 billion; underlying sales grew 14 percent.
TAVR sales grew 15 percent; underlying 14 percent.
U.S. TAVR sales grew 12 percent; OUS approximately 20 percent.
Continued progress on five pivotal trials in TMTT.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
The company expects full year 2021 sales to fall within the previous guidance range of $5.2 to $5.4 billion and adjusted earnings per share guidance at the high end of $2.07 to $2.27. For the fourth quarter of 2021, the company projects sales to be between $1.30 and $1.38 billion, including TAVR between $850 and $910 million, and adjusted EPS of $0.53 to $0.59.
Positive Outlook
- Full year 2021 sales guidance range unchanged
- Full year EPS guidance remains unchanged
- Company projects sales to be between $1.30 and $1.38 billion for Q4 2021
- TAVR sales for Q4 2021 projected between $850 and $910 million
- Adjusted EPS of $0.53 to $0.59 for Q4 2021
Challenges Ahead
- Headwinds associated with the pandemic
- Some procedures were deferred in the third quarter due to the Delta variant
- TAVR sales were negatively impacted in the last two months of the third quarter due to the significant impact COVID had on hospital resources.
- Uncertainties related to the impact of the pandemic
- Potential for further deferral of procedures
Revenue & Expenses
Visualization of income flow from segment revenue to net income